Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harboring KRAS G12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect antitumor immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have characterized how KRAS G12C inhibition reverses immunosuppression driven by oncogenic KRAS in a number of preclinical lung cancer models with varying levels of immunogenicity. Mechanistically, KRAS G12C inhibition up-regulates interferon signaling via Myc inhibition, leading to reduced tumor infiltration by immunosuppressive cells, enhanced infiltration and activation of cytotoxic T cells, and increased antigen presentation. However, the combination of KRAS G12C inhibitors with immune checkpoint blockade only provides synergistic benefit in the most immunogenic tumor model. KRAS G12C inhibition fails to sensitize cold tumors to immunotherapy, with implications for the design of clinical trials combining KRAS G12C inhibitors with anti-PD1 drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Research works printed but not linked: 27
- 10.3322/caac.21492 · DOI · Paper page
- 10.3322/caac.21590 · DOI · Paper page
- 10.1038/nm.2697 · DOI · Paper page
- 10.3390/cancers13010151 · DOI · Paper page
- 10.1126/science.aaa1348 · DOI · Paper page
- 10.1158/1078-0432.CCR-18-3904 · DOI · Paper page
- 10.1084/jem.20201414 · DOI · Paper page
- 10.1038/s41467-021-26214-x · DOI · Paper page
- J. Boumelha S. de Carné Trécesson E. K. Law P. Romero-Clavijo M. A. Coelho K. Ng E. Mugarza C. Moore S. Rana D. R. Caswell M. Murillo D. C. Hancock P. P. Argyris W. L. Brown C. Durfee L. K. Larson R. I. Vogel A. Suárez-Bonnet S. L. Priestnall P. East S. J. Ross G. Kassiotis M. Molina-Arcas C. Swanton R. Harris J. Downward An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations. bioRxiv 2020.12.22.423126 [Preprint]. 17 January 2022. https://doi.org/10.1101/2020.12.22.423126. · doi:10.1101/2020.12.22.423126
- 10.1073/pnas.2025570118 · DOI
- 10.3390/genes12060899 · DOI · Paper page
- 10.1038/sj.onc.1209237 · DOI · Paper page
- 10.1038/s41467-020-19288-6 · DOI · Paper page
- 10.1016/S1470-2045(16)00078-4 · DOI · Paper page
- 10.1016/j.ccell.2016.04.014 · DOI · Paper page
- Y. Zhu, W. G. Hawkins, D. G. DeNardo, Regramming myeloid responses to improve cancer immunotherapy. Onco. Targets Ther. 4, e974399 (2015).
- 10.1158/2159-8290.CD-19-1409 · DOI · Paper page
- 10.1158/1078-0432.CCR-19-3524 · DOI
- B. Seliger, C. Harders, U. Wollscheid, M. S. Staege, A. B. Reske-Kunz, C. Huber, Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol. 24, 1275–1279 (1996).
- 10.1002/ijc.11681 · DOI · Paper page
- 10.1038/s41573-018-0007-y · DOI · Paper page
- 10.1038/nrc.2017.17 · DOI · Paper page
- 10.1126/scitranslmed.aaa4691 · DOI · Paper page
- 10.1158/1078-0432.CCR-15-1125 · DOI · Paper page
- 10.1007/s11912-016-0531-z · DOI
- 10.1038/s41591-019-0476-5 · DOI · Paper page
- 10.1158/0008-5472.CAN-19-3038 · DOI · Paper page
Cited by
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Self-citationAraujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0421 · Cited by 70
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03401-z · Cited by 42
Foote, J. B., Mattox, T. E., Keeton, A. B., Chen, X., Smith, F., Berry, K. L., Holmes, T., Wang, J., Huang, C.-H., Ward, A. B., et al. (2023) · doi:10.1101/2023.05.17.541233 · Cited by 13
Metadata
- Authors
- Mugarza, E., van Maldegem, F., Boumelha, J., Moore, C., Rana, S., Llorian Sopena, M., East, P., Ambler, R., Anastasiou, P., Romero-Clavijo, P., Valand, K., Cole, M., Molina-Arcas, M., & Downward, J.
- Venue
- Science Advances
- Published
- 2022-07-22
- Volume
- 8
- Issue
- 29
- Pages
- eabm8780-eabm8780
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W4285987606
- Cited by
- 142
- References
- 26
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.